Spotlight on Recent Biodesix Presentations
December 2023 | CHEST Journal
Using a Blood Biomarker to Distinguish Benign From Malignant Pulmonary Nodules - A Subgroup Analysis Comparing Screen Detection, Sex, Smoking History, and Nodule Size
Authors:
Katheryn J. Long, Trevor Pitcher, PhD. (Biodesix), Jonathan S. Kurman, MD. Michael A. Pritchett, DO. Gerard A. Silvestirti, MD.
Biodesix Announces New Clinical and Economic Data for its Nodify Lung® Tests at ISPOR and ATS.
“Time to Diagnosis of Lung Cancer from Identification of a Pulmonary Nodule in the United States” by Kimberly Le, Biodesix Director of Health Economics and Outcomes Research at ISPOR 2025.
“Utilization of Proteomic Testing in Pulmonary Nodule Risk Stratification at a Safety-Net Hospital: An Observational Study” by Sonu Sahni, MD, Director of Lung Cancer Screening at Wyckoff Heights Medical Center in New York at the ATS 2025 Conference
May 2025 | ASCO 2025
Host immune classifier to predict survival with chemoimmunotherapy in PD-L1 ≥50% metastatic NSCLC
Presented by:
Dr. Vamsidhar Velcheti, MD, Director of Thoracic Oncology at NYU Langone’s Perlmutter Cancer Center
Upcoming Biodesix Presentations and Events
Speaker: Emma Longshore, Bioinformatician, Biodesix
August 27, 2025 at 1 PM EDT | Webinar | CAP TODAY / Thermo Fisher Scientific Webinar: Introduction of new FDA approved rapid NGS solution for Companion Diagnostics & tumor profiling in oncologySpeakers: Gary Pestano, Ph.D., Chief Development Officer, Biodesix; David Chi, PhD, Thermo Fisher Scientific; and Bence Sipos, MD
September 13 – 16, 2025 | Orlando, FL | College of American Pathologists (CAP) 2025 Annual MeetingSeptember 15th at 12 PM EDT| "Introduction of new IVD solution for rapid NGS profiling in Oncology Sponsored by Thermo Fisher Scientific"
Speakers: Gary Pestano, Ph.D., Chief Development Officer, Biodesix; Mahmoud Elsayad, MD, FCAP, University of Texas Health; and Alison Roos, Thermo Fisher Scientific
September 16 – 18, 2025 | Boston, MA | 7th Annual RAS-Targeted Drug Development SummitSeptember 17th at 9:30 AM EDT| Presentation on "Rapid Turnaround Liquid Biopsy testing in the Evaluation of RAS Mutational Status During Treatment"
Speaker: Michael Sweeney, Director - Alliance Management & Business Development, Biodesix
September 22 – 25, 2025 | Boston, MA | 15th Annual World CB & CDx SummitSeptember 24th at 11:20 AM EDT| Presentation on "Driving Drug Development with Integrated Multi-Omic Insights: Unlocking Precision Medicine with Biodesix’ Comprehensive Service Offerings"
Speaker: Colin McDowell, Ph.D., Senior Manager - Business Development, Biodesix
October 9 – 11, 2025 | Denver, CO | GO2 for Lung Cancer 2025 Centers of Excellence Summit October 19 – 22, 2025 | Chicago, IL | CHEST 2025View Past Biodesix Presentations and Events
Session by Leisa Jackson, Biodesix Staff Scientist, on Development of a Highly Sensitive and Specific Droplet Digital PCR Assay for Multiplexed Detection and Longitudinal Monitoring of ESR1 Variants in Plasma: A QX600 Case Study
73rd Conference on Mass Spectrometry and Allied Topics
Poster presentation by Amanda Weaver, Biodesix Staff Scientist, on "Clinical Results of a mCRPC Cohort with Automated MALDI-TOF Sample Preparation Utilizing the Felix Liquid Handler and Active Drier"
Poster presentation by Sarah Phillips, Biodesix Senior Scientist, on "Optimizing Testing Capacity for a Clinical Proteomics MRM Assay: Expanding HPLC and Plate-Based Depletion Methods"
Poster presentation by Kimberly Le, PharmD, Biodesix Director of HEOR, on Time to Diagnosis of Lung Cancer From Identification of a Pulmonary Nodule in the United States.
Life Sciences - In Focus: Laboratory Developed Tests: What Now, Where Next?
Panel Discussion with Tristin Wolff Cope, Director of Regulatory Compliance. Sponsored by Vistatec and RAPS Colorado Chapter.
ATS 2025 International Conference
Friends of Cancer Research Advancing the Future of Diagnostics and Regulatory Innovations White Paper co-authored Gary Pestano, Ph.D., Chief Development Officer, Biodesix and Brianna Phillips, Vice President of Quality and Regulatory Affairs, Biodesix: Innovative Validation and Regulatory Processes for Companion Diagnostic Tests for Rare Biomarkers or Indications
ISPOR Europe 2024 Poster presentations by Kimberly Le, PharmD, Director of Health Economics Outcomes Research, Biodesix:
- EPH31: Incidence of Pulmonary Nodules (PNs) During the Coronavirus Disease (COVID-19) Pandemic in the United States (US)
- EPH93: Prevalence of Pulmonary Nodules (PNs) in 2020 During the Coronavirus Disease (COVID-19) Pandemic in the United States (US)
- EE438: Economic Impact Model to Estimate the Value of Blood-Based Biomarkers in the Risk Assessment of Pulmonary Nodules (PNS) From a Health System Perspective
- EPH208: Prevalence of Pulmonary Nodules (PNs) in 2019 in the United States (US)
- EHP209: Incidence of Pulmonary Nodules (PNs) in 2019 in the United States (US)
- CO183: Clinical Impact Model for Blood-Based Biomarkers in the Risk Assessment of Pulmonary Nodules (PNs) From a Health System Perspective
AACR Special Conference in Cancer Research: Liquid Biopsy: From Discovery to Clinical Implementation Poster Presentation by Colin McDowell, Ph.D. Senior Manager of Business Development, Biodesix: A032 Performance evaluation of a new protein stabilizing blood collection tube with a novel whole blood separation device for clinical plasma proteomics
Droplet Digital PCR World 2024 Asia Presentation by Gary Pestano, Ph.D., Chief Development Officer, Biodesix: From Feasibility to Clinical Testing for Rare Variants in Oncology: 10 years of ddPCR Experiences